'Trial suggests methotrexate might prolong and, to a lesser extent, increase the effectiveness of intra-articular corticosteroid therapy in oligoarticular JIA. Although no difference in primary outcome in the intention-to-treat analysis, imputed covariate and outcome data with multivariable logistic regression and Cox proportional hazards model favoured methotrexate arm.' Unfortunately, the latter statement would require the Twitter author to have read the original paper and uses 371 characters, far above the limit imposed.
The second consideration is that indirect information often becomes corrupt. Everyone is familiar with the childhood game in which one person whispers a message to the ear of the next person through a line of people until the last player announces the message to the entire group, revealing how errors accumulate in retelling. The explanations are simple and include impatience, mistaken corrections, the difficult-to-understand nature of whispering, and sometimes deliberate intervention. Twitter is perhaps the ultimate whispering game: information is collated by an index user (maybe in a rush), and shared to their network of followers; a number of followers may then quote or retweet the original user and so forth. As an example, the BMJ published an article on vitamin D supplementation [4, 5] . The day before publication, @BMJ released a Tweet: 'Study reports a new indication for #vitaminD supplementation: the prevention of acute respiratory tract infection https:// t.co/WJYLEj72H1'. Over the following 5 days, 802 Twitter users commented on the study, with the full spectrum of possible interpretations endorsed: that the study shows nothing through to claiming that the study confirms vitamin D cures the common cold.
A third consideration is that Tweets are anonymous. Of course, physicians are familiar with the tabloid nature of some medical journalism. The challenge with Twitter is that the authors are largely anonymous, tagged not by a name but instead a pseudo anonymized Twitter handle, or even simply the name of a medical journal, without any visible attribution to an actual individual. With traditional media sources, a reader can look at the publication title and draw judgement on the likely integrity of the report, but this is not possible in the same way with Twitter. This means that there is the potential for some news resources to be posting information that is unreliable, or could be used in a detrimental way, possibly towards other Twitter users.
Lastly the impact may be misleading. Of interest to some readers will be the potential of Twitter to disseminate research. For our academic readers, achieving impact is highly prized. @RheumJnl Tweeted daily over the last month, totalling over 35 000 impressions (views of a Tweet) across the globe (34% UK, 21% USA). What remains unknown is how Twitter activity influences traditional impact. Web traffic to articles mentioned in Twitter increases, but influence upon citations is unknown. Altmetric has emerged in recent years as a nontraditional alternative to more citation metrics, such as impact factor and h-index (readers may have noticed Altmetric scores in the journal appearing online inside a multi-coloured circle to the right of articles). Altmetric rates an article according to aspects of impact such as how many data and knowledge bases refer to it, article views, downloads or mentions in social media and news outlets. However, both success and infamy improve the Altmetric score.
Despite these caveats, Twitter and other social media are clearly becoming a regular source of medical information for many of us in the rheumatology world. It is therefore important that we learn how best to view and interpret these 140 character comments.
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